131 related articles for article (PubMed ID: 12451677)
1. [Clinical importance of serum anti-p53 antibodies as tumor markers].
Sakai H; Okamoto E
Rinsho Byori; 2002 Oct; 50(10):970-5. PubMed ID: 12451677
[TBL] [Abstract][Full Text] [Related]
2. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers.
Müller M; Meyer M; Schilling T; Ulsperger E; Lehnert T; Zentgraf H; Stremmel W; Volkmann M; Galle PR
Int J Oncol; 2006 Oct; 29(4):973-80. PubMed ID: 16964393
[TBL] [Abstract][Full Text] [Related]
3. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China.
Qiu LL; Hua PY; Ye LL; Wang YC; Qiu T; Bao HZ; Wang L
Cancer Detect Prev; 2007; 31(1):45-9. PubMed ID: 17292563
[TBL] [Abstract][Full Text] [Related]
4. [Detection of serum anti-p53 antibodies in patients with various types of cancer].
Sakai H
Rinsho Byori; 2002 Jan; 50(1):90-2. PubMed ID: 11871143
[TBL] [Abstract][Full Text] [Related]
5. Anti-P53 antibodies in Brazilian brain tumor patients.
Fonseca RF; Kawamura MT; Oliveira JA; Teixeira A; Alves G; Carvalho Mda G
Genet Mol Res; 2003 Jun; 2(2):185-90. PubMed ID: 14966683
[TBL] [Abstract][Full Text] [Related]
6. Serum anti-p53 in relation to mutations across the entire translated p53 gene in colorectal carcinomas.
Forslund A; Kressner U; Lindmark G; Inganäs M; Lundholm K
Int J Oncol; 2001 Sep; 19(3):501-6. PubMed ID: 11494027
[TBL] [Abstract][Full Text] [Related]
7. p53 antibodies in patients with various types of cancer: assay, identification, and characterization.
Lubin R; Schlichtholz B; Teillaud JL; Garay E; Bussel A; Wild CP
Clin Cancer Res; 1995 Dec; 1(12):1463-9. PubMed ID: 9815945
[TBL] [Abstract][Full Text] [Related]
8. Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity.
Castelli M; Cianfriglia F; Manieri A; Palma L; Pezzuto RW; Falasca G; Delpino A
Anticancer Res; 2001; 21(1B):753-8. PubMed ID: 11299839
[TBL] [Abstract][Full Text] [Related]
9. p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.
Creaney J; McLaren BM; Stevenson S; Musk AW; de Klerk N; Robinson BW; Lake RA
Br J Cancer; 2001 Jan; 84(1):52-6. PubMed ID: 11139313
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.
Gadducci A; Ferdeghini M; Buttitta F; Fanucchi A; Annicchiarico C; Prontera C; Bevilacqua G; Genazzani AR
Anticancer Res; 1996; 16(6B):3519-23. PubMed ID: 9042215
[TBL] [Abstract][Full Text] [Related]
11. Serum anti-p53 autoantibodies from patients with idiopathic pulmonary fibrosis associated with lung cancer.
Oshikawa K; Sugiyama Y
Respir Med; 2000 Nov; 94(11):1085-91. PubMed ID: 11127496
[TBL] [Abstract][Full Text] [Related]
12. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: a multiinstitutional analysis by the Japan p53 Antibody Research Group.
Shimada H; Ochiai T; Nomura F;
Cancer; 2003 Feb; 97(3):682-9. PubMed ID: 12548611
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection.
Megliorino R; Shi FD; Peng XX; Wang X; Chan EK; Tan EM; Zhang JY
Cancer Detect Prev; 2005; 29(3):241-8. PubMed ID: 15896923
[TBL] [Abstract][Full Text] [Related]
14. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
15. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies.
Looi K; Megliorino R; Shi FD; Peng XX; Chen Y; Zhang JY
Oncol Rep; 2006 Nov; 16(5):1105-10. PubMed ID: 17016600
[TBL] [Abstract][Full Text] [Related]
16. [Serum anti-p53 antibodies in gastric cancer patients].
Lawniczak M; Bielicki D; Sulzyc-Bielicka V; Marlicz K; Starzyńska T
Pol Merkur Lekarski; 2007 Sep; 23(135):192-5. PubMed ID: 18080693
[TBL] [Abstract][Full Text] [Related]
17. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
18. Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma.
Gadducci A; Ferdeghini M; Buttitta F; Cosio S; Fanucchi A; Annicchiarico C; Genazzani AR
Anticancer Res; 1998; 18(5B):3763-5. PubMed ID: 9854491
[TBL] [Abstract][Full Text] [Related]
19. Gene p53 mutations, protein p53, and anti-p53 antibodies as biomarkers of cancer process.
Lutz W; Nowakowska-Swirta E
Int J Occup Med Environ Health; 2002; 15(3):209-18. PubMed ID: 12462448
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]